טוען...
Androgen Receptor Promotes Tamoxifen Agonist Activity by Activation of EGFR in ERα-Positive Breast Cancer
PURPOSE: Tamoxifen (Tam) resistance represents a significant clinical problem in estrogen receptor (ER) -positive breast cancer. We previously showed that decreased expression of Rho guanine nucleotide dissociation inhibitor (Rho GDI), a negative regulator of the Rho GTPase pathway, is associated wi...
שמור ב:
| הוצא לאור ב: | Breast Cancer Res Treat |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4749407/ https://ncbi.nlm.nih.gov/pubmed/26487496 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3609-7 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|